Overview

Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications

Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
Sugammadex or neostigmine are given at the end of the surgery to reverse neuro muscular blocking drugs. This study will evaluate whether reversal of NMBD with sugammadex is associated with faster recovery than neostigmine resulting in faster discharge from the operating room (OR) in obese patients with OSA undergoing bariatric surgery. Half of the patients in the study will receive sugammadex and the other half of the patients will receive neostigmine.
Phase:
Phase 4
Details
Lead Sponsor:
University Health Network, Toronto
Collaborator:
Merck Canada Inc.
Treatments:
Neostigmine